Mining and analysis of adverse events of bevacizumab in ovarian cancer patients based on FAERS database

GAO Meng; WU Yu-pei; WANG Miao-miao; WU Hui-zhen

doi:10.20251/j.cnki.1003-3734.2026.11.012

Abstract：Objective:To mine the adverse events(AEs)related to bevacizumab in ovarian cancer patients from the FDA Adverse Event Reporting System(FAERS)and to reveal their clinical priority information,so as to provide a reference for clinical medication.Methods:AE reports related to bevacizumab for ovarian cancer were collected from the FAERS database from the first quarter of 2004(Q1)to the first quarter of 2025(Q1).Signal mining was performed using the reporting odds ratio(ROR),proportional reporting ratio(PRR)and Bayesian Confidence Propagation Neural Network(BCPNN)methods,and clinical priority assessment of positive signals was conducted.Results:A total of 5025 reports were include.Physicians were the primary reporters(60.23%),and the United States accounted for the largest proportion of reporters(36.16%).A total of 195 preferred term(PT)signals were identified,spanning 20 System Organ Classes(SOCs).General disorders and administration site conditions was the most frequently reported SOC.Common AEs included hypertension,proteinuria and neutropenia,etc.The median onset time of all AEs was 81 days.Clinical priority classification:2 PTs were classified as strong priority,62 PTs as moderate priority,and 131 PTs as weak priority.The strong priority PTs were intestinal perforation and gastrointestinal perforation.Conclusion:Based on an extensive analysis of the post-marketing international safety database,this study identified common AEs associated with bevacizumab in ovarian cancer patients,and highlighted the need for close monitoring of intestinal perforation and gastrointestinal perforation,providing a reference for clinical medication and pharmacovigilance.